פרגבלין תרו 150 מג
taro international ltd, israel - pregabalin - קפסולות - pregabalin 150 mg - pregabalin
פרגבלין תרו 200 מג
taro international ltd, israel - pregabalin - קפסולות - pregabalin 200 mg - pregabalin
פרגבלין תרו 225 מג
taro international ltd, israel - pregabalin - קפסולות - pregabalin 225 mg - pregabalin
פרגבלין תרו 300 מג
taro international ltd, israel - pregabalin - קפסולות - pregabalin 300 mg - pregabalin
פרגבלין תרו 75 מג
taro international ltd, israel - pregabalin - קפסולות - pregabalin 75 mg - pregabalin
ג'קאבי 5 מג
novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 5 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.
ג'קאבי 15 מג
novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 15 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.
ג'קאבי 20 מג
novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 20 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.
ג'קאבי 10 מג
novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 10 mg - ruxolitinib
אקטיק 200 מקג
abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 200 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.